Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets-Reference-Cited by-同舟云学术

Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets

Published:2004-11-15 Issue:22 Volume:78 Page:12672-12676
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Weingartl Hana¹²,Czub Markus³²,Czub Stefanie¹²,Neufeld James¹,Marszal Peter¹,Gren Jason¹,Smith Greg¹,Jones Shane³,Proulx Roxanne³,Deschambault Yvonne³,Grudeski Elsie³,Andonov Anton³²,He Runtao³²,Li Yan³²,Copps John¹,Grolla Allen³,Dick Daryl³,Berry Jody¹²,Ganske Shelley¹,Manning Lisa¹,Cao Jingxin³²

Affiliation:

1. National Centre for Foreign Animal Diseases

2. Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2

3. National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba, Canada R3E 3R2

Abstract

ABSTRACT Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) is a serious emerging human infectious disease. In this report, we immunized ferrets ( Mustela putorius furo ) with recombinant modified vaccinia virus Ankara (rMVA) expressing the SARS-CoV spike (S) protein. Immunized ferrets developed a more rapid and vigorous neutralizing antibody response than control animals after challenge with SARS-CoV; however, they also exhibited strong inflammatory responses in liver tissue. Inflammation in control animals exposed to SARS-CoV was relatively mild. Thus, our data suggest that vaccination with rMVA expressing SARS-CoV S protein is associated with enhanced hepatitis.

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.78.22.12672-12676.2004

Reference20 articles.

1. Berry, J. D., S. Jones, M. A. Drebot, A. Andonov, M. Sabara, X. Y. Yuan, H. Weingartl, L. Fernando, P. Marszal, J. Gren, B. Nicolas, M. Andonova, F. Ranada, M. J. Gubbins, T. B. Ball, P. Kitching, Y. Li, A. Kabani, and F. Plummer. 2004. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J. Virol. Methods120:87-96.

2. Bisht, H., A. Roberts, L. Vogel, A. Bukreyev, P. L. Collins, B. R. Murphy, K. Subbarao, and B. Moss. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA101:6641-6646.

3. Chakrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques23:1094-1097.

4. Chau, T. N., K. C. Lee, H. Yao, T. Y. Tsang, T. C. Chow, Y. C. Yeung, K. W. Choi, Y. K. Tso, T. Lau, S. T. Lai, and C. L. Lai. 2004. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology39:302-310.

5. Collins, A. R., R. L. Knobler, H. Powell, and M. J. Buchmeier. 1982. Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusion. Virology119:358-371.

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

2. Beyond COVID-19: the promise of next-generation coronavirus vaccines;npj Viruses;2024-08-22

3. No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model;PLOS ONE;2024-06-20

4. Observation of dichotomic field-tunable electronic structure in twisted monolayer-bilayer graphene;Nature Communications;2024-05-03

5. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus;Nature Communications;2024-05-03